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Abstract
We recently constructed a novel non-replicating dominant-negative HSV-2 recombinant viral vaccine (CJ2-gD2) capable of
expressing various HSV-2 antigens that are dominant targets of HSV-2-specific CD8 T-cell response. Importantly, CJ2-gD2
expresses gD2, the HSV-2 major antigen glycoprotein D, as efficiently as wild-type HSV-2 infection and can lead to a nearly
500-fold reduction in wild-type HSV-2 viral replication in cells co-infected with CJ2-gD2 and wild-type HSV-2. In this report,
we show that CJ2-gD2 elicits a strong antibody response to various HSV-2 antigens and is highly effective in the prevention
of primary and recurrent HSV-2 genital infection and disease in the immunized guinea pigs. The direct comparison study
between CJ2-gD2 and a gD2 subunit vaccine (gD2-alum/MPL) with a formulation akin to a vaccine tested in phase III clinical
trials shows that CJ2-gD2 is 8 times more effective than the gD2-alum/MPL subunit vaccine in eliciting an anti-HSV-2 specific
neutralizing antibody response and offers significantly superior protection against primary and recurrent HSV-2 genital
infections. Importantly, no challenge wild-type HSV-2 viral DNA was detectable in dorsal root ganglia DNA isolated from
CJ2-gD2-immunized guinea pigs on day 60 post-challenge. CJ2-gD2 should be an excellent HSV-2 vaccine candidate for
protection against HSV-2 genital infection and disease in humans.
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Introduction
Genital herpes is one of the most common sexually transmitted
diseases worldwide and is the primary cause of genital ulcer disease
in both developed and developing countries [1]. Herpes simplex
virus type 2 (HSV-2) is the primary cause of recurrent genital
herpes. Approximately fifty to sixty million adults in the United
States are infected with HSV-2 [2,3]. HSV infections can cause
significant clinical problems in AIDS and cancer patients, organ
transplant recipients, and newborns [4]. Moreover, genital HSV-2
infection triples the risk for sexual acquisition and transmission of
HIV infection [5]. Currently, no antiviral therapy is effective in
preventing or reducing the incidence of symptomatic and
asymptomatic HSV-2 recurrent infections with the exception of
daily suppressive therapy. Thus, there is a strong need to develop
safe and efficacious vaccines against HSV-2 infection [1,6,7].
Using the T-REx gene switch technology (Invitrogen Inc., CA)
developed in this laboratory, we constructed a novel class of
replication-defective HSV-1 recombinants capable of blocking
wild-type HSV-1 and HSV-2 infections (dominant-negative) [8,9].
CJ9-gD is a prototype of a non-replicating dominant-negative
HSV-1 viral vaccine, which encodes 2 copies of the dominant-
negative mutant polypeptide UL9-C535C of HSV-1 origin of viral
replication binding protein UL9 under the control of the tetO-
containing hCMV immediate-early promoter (CMVTO) and a
single copy of the HSV-1 glycoprotein D (gD) gene under driven
by CMVTO [10]. CJ9-gD is completely replication-defective,
cannot establish detectable latent infection in vivo, and expresses
high levels of HSV-1 major antigen glycoprotein D (gD)
independent of HSV-1 viral DNA replication [10]. Immunization
with CJ9-gD elicits a strong and long-term protective immune
response against HSV-1 infection in mouse and guinea pig models
of HSV-1 infections [10–12].
Given these demonstrated favorable safety and immunological
profiles of CJ9-gD and the hypothesis that HSV-2 recombinant
virus-based vaccine would be significantly superior to the HSV-1
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constructed an HSV-2-based non-replicating dominant-negative
recombinant virus, CJ2-gD2. To maximize the HSV-2 glycopro-
tein D (gD2) expression by CJ2-gD2, we replaced both copies of
the HSV-2 ICP0 gene with a bi-directional transcription unit that
encodes the full-length gD2 gene driven by the tetO-bearing HSV-
1 ICP4 promoter and the UL9-C535C gene under the control of
CMVTO [13]. While CJ2-gD2 expresses little gD2 in tetracycline
repressor (tetR)-expressing cells, it expresses gD2 as efficiently as
wild-type HSV-2 infection in non tetR-expressing cells. CJ2-gD2 is
avirulent and incapable of establishing detectable latent infection
following immunization. We demonstrate that high-level expres-
sion of gD2 by CJ2-gD2 leads to a significant increase in its
efficacy in eliciting anti-HSV-2-specific neutralizing antibody
response and protective immunity against wild-type HSV-2 genital
infection and disease in mice compared with a non-gD2-
expressing non-replicating dominant-negative HSV-2 recombi-
nant virus [13]. Moreover, compared with live CJ2-gD2, uv-
inactivated CJ2-gD2 was ineffective in protecting against HSV-2
genital infection, indicating that de novo viral antigen expression
by CJ2-gD2 is required for the demonstrated vaccine efficacy
against HSV-2 infection [13].
Unlike the mouse model of HSV-2 genital infection in which
spontaneous reactivation from latent infection rarely occurs in the
vaginal tract, guinea pigs experience episodic spontaneous
recurrent infection and disease following recovering from primary
HSV-2 genital infection [14,15]. Moreover, after primary HSV-2
intravaginal infection, guinea pigs develop vesicular lesions similar
to those in humans, which include development, appearance, and
duration of disease. In the current study, we investigated the
vaccine efficacy of CJ2-gD2 in the guinea pig model of HSV-2
genital infection and whether CJ2-gD2 would represent a better
vaccine candidate than the gD2 subunit vaccine formulated with
alum/MPL in protecting against HSV-2 infection. We show that
CJ2-gD2 is highly effective in preventing primary and recurrent
genital herpes infections and disease in the immunized animals.
Moreover, CJ2-gD2 is significantly superior to gD2-alum/MPL
subunit vaccine in eliciting anti-HSV-2 specific neutralizing
antibody response as well as protective immunity against primary
and recurrent HSV-2 genital infections.
Materials and Methods
2.1. Ethics Statement
All animal experiments conducted in this study were approved
by the Harvard Medical Area Standing Committee on Animals
and the American Veterinary Medical Association (Protocol
Number: 03167), which is accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC) and meets National Institutes of Health standards as
set forth in ‘‘The Guide for the Care and Use of Laboratory
Animals.’’
2.2. Cells, viruses and subunit vaccines
Vero cells were grown and maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM; Sigma) supplemented with 10% fetal
bovine serum (FBS) [16]. U2OS cells are an human osteosarcoma
line that can complement functionally for the HSV-1 and HSV-2
ICP0 deletions [13,16]. U2CEP4R11 cells, an U2OS cells derived
tetR-expressing cell line, were grown in DMEM containing 10%
FBS and hygromycin B [17].
Wild-type HSV-2 strains, MS and 186, were propagated and
plaque assayed in Vero cells. CJ2-gD2 is an HSV-2 strain 186-
derived ICP0-null mutant-based non-replicating dominant-nega-
tive recombinant virus encoding the gD2 gene driven by the tetO-
bearing HSV-1 ICP4 promoter and the UL9-C535C gene under
the control of the truncated form of hCMVTO [13]. UL9-C535C
consists of Met-Gly followed by the C-terminal amino acids 535-
851 of the UL9 protein [18]. CJ2-gD2 was propagated and plaque
assayed in U2CEP4R11 cells [13]. The titer of CJ2-gD2 stock used
in this study was 1.45610
8 PFU/ml on U2CEP4R-11 cell
monolayers.
The recombinant gD2 protein, produced from CHO cells stably
expressing a truncated form of gD2 polypeptide consisting of
amino acids 1 - 306 of the mature gD2 with NQG3H9 appended
to the C-terminal, was purified at Merck Research Laboratories,
West Point, PA [19]. The gD2 coding sequence is derived from
HSV-2 strain G. The gD2-alum/MPL subunit vaccine was freshly
prepared prior to each immunization in a formulation similar to
that described by Bourne et al. [20] and Awashthi et al [19]. In
brief, 30 mg of the recombinant gD2 protein was first mixed with
750 mg of alum (Imject Alum, Thermo Scientific, Rockford, IL) in
a volume of 850 ml on a rotating platform. After 30 minuntes of
incubation at room temperature, 75 mg of Monophosphoryl Lipid
A (MPL) (Avanti Polar Lipids, Inc., Alabaster, AL) was added to
gD2-alum solution followed by gentle mixing. MPL stock solution
was prepared at a concentration of 500 mg/ml containing 10%
DMSO (Sigma Aldrich) and store at -20uC (InvivoGen, San
Diego, CA).
2.3. Immunization and challenge
Female Hartley guinea pigs (300-350 g) were obtained from
Charles River Laboratories (Wilmington, MA). Animals were
randomly assigned to three groups of eight animals each in the first
experiment and three groups of 6six to eight each in the second
experiment. Each of the groups was either sham-immunized with
DMEM (n=8, 8), immunized with gD2-alum/MPL at a dose of
3 mg of gD2/animal (n=8, 6) as described by Hoshino et al. [21],
or immunized with CJ2-gD2 at a dose of 5610
6 PFU/animal
(n=8, 6). Each vaccine was administered by i.m. into the
quadriceps of the left and right hind limbs in a volume of 50 ml
per injection [20,22]. Consistent with the vaccination regimen in
GSK’s phase III clinical trials, in which gD2-alum/MPL subunit
vaccine was administered 3 times [23,24], guinea pigs were
boosted with gD2-alum/MPL or CJ2-gD2 on days 14 and 28 post
primary immunization. Anesthetized sham-immunized and im-
munized animals were preswabbed with a moist sterile calcium
alginate swab (Calgiswab type 2, Puritan Medical Products
Company LLC, Maine USA) and challenged intravaginally with
5610
5 PFU of HSV-2 strain MS at 3 weeks after the third
immunization in experiment 1 and at 2 weeks after the third
immunization in experiment 2 [22]. Since the demonstrated
efficacy of each immunogen in protecting against HSV-2 genital
infection and disease is essentially the same across both
experiments, the results from the corresponding groups in each
experiment have been combined and are presented together in this
study.
2.4. Clinical observations
After challenge with wild-type HSV-2, the animals were
examined daily until day 60 post-challenge. The number of
lesions for individual animals was counted and the disease was
scored non-blindly as previously described [22]: 0= no disease;
1= redness or swelling; 2= a few small vesicles; 3= several large
vesicles; 4= several large ulcers with maceration; 5= paralysis;
and 6= death.
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challenge virus
Animals were anesthetized and vaginal mucosae were swabbed
on days 1, 2, 3, 5, 7, and 9 post-challenge. Materials on individual
swabs were suspended in 1 ml of DMEM containing 10% FBS in
the presence of 100 U/ml penicillin G and 100 mg/ml of
streptomycin sulfate (Gibco, Carlsbad, CA). Infectious virus on
swab materials was assessed by standard plaque assay in 60-mm
dishes of Vero cells. The minimum titer of challenge virus that
could be detected was 1 PFU per original vaginal swab materials.
For analysis of recurrent virus shedding, swabs were taken daily
from days 21 to 50 post challenge. DNA was isolated from swab
materials with the DNeasy tissue kit (Qiagen, Santa Clarita, CA),
and stored at 220 C.
2.6. Neutralizing antibody assay
Blood was obtained from the saphenous veins at weeks 2, 4 and
6 or 7 post-primary immunization. HSV-2-specific neutralizing
antibody titers in serum collected from each animal were
determined in the presence of complement as described previously
[20,25]. In brief, serum prepared from individual animals was first
heat-inactivated followed by a series of two-fold dilutions with
normal growth medium containing amphotericin-B at 50 mg/ml
and Low Tox M rabbit C (Accurate Chemical and Scientific,
Westbury) at 15-fold final dilution. 250 PFU of wild-type HSV-2
strain 186 was added to the diluted serum or titration growth
medium in the presence of Low Tox M rabbit C in a final volume
of 600 ml. After incubation at 37uC for 1 h, HSV-2 titers were
determined in duplicate 60-mm dishes of Vero cells by standard
plaque assays under growth medium containing 5% FBS and 2%
methylcellulose (M352-500, Fisher Scientific). The neutralizing
titer was expressed as the final serum dilution required to achieve a
50% reduction in HSV-2 PFU relative to the HSV-2 PFU
obtained in media plus complement alone. The results are
presented as the mean 6 SEM.
2.7. Western blot analysis
60-mm dishes of Vero cells in duplicate were mock-infected or
infected with wild-type HSV-2 strain 186 at an MOI of 5 PFU/
cell at 42 h post-seeding. Cell extracts were prepared at 16 h post-
infection [16]. To further investigate immunization in eliciting gD-
specific antibody response, U2OS cells were mock-transfected or
transfected with a gD2-encoding plasmid, p02.4TO-gD2 [13] and
cell extracts were prepared at 48 h post-transfection. Proteins in
the cell extracts were resolved on SDS-PAGE followed by western
blot analysis with guinea pig serum pooled from an equal volume
of serum collected from sham control, CJ2-gD2-immunized
animals (n=8) or gD2-alum/MPL-immunized animals (n=8)
described in the first experiment in section 2.3 two weeks after the
third immunization at a dilution of 1:200. After 1 h incubation at
room temperature, the membranes were washed and reacted with
HRP-conjugated goat-anti-guinea pig IgG (sc-2438, Santa Cruz
Biotechnology, Santa Cruz, CA). Similar results were obtained
when the described western blot analyses were repeated or
performed with pooled serums prepared from an equal volume of
serum collected from CJ2-gD2-immunized animals (n=6) or gD2-
alum/MPL-immunized animals (n=6) 2 weeks after the third
immunization in the second experiment described under section
2.3.
2.8. Quantitative real-time PCR
On day 60 post-challenge, twelve lower lumbar and sacral
dorsal root ganglia (DRG) per guinea pig were collected from
individual guinea pigs immunized with CJ2-gD2 or gD2-Alum/
MPL. The dorsal root ganglia DNA was extracted using the
DNeasy tissue kit (Qiagen, Santa Clarita, CA), and suspended in
100 ml AE buffer. As a control, the DRG DNA was also isolated
from four shamed-immunized guinea pigs euthanized on days 17,
18, 23, and 30, respectively, post-challenge due to the severity of
local and systemic illness caused by HSV-2 infection. The presence
of HSV-2 DNA was quantified by real-time PCR (Applied
Biosystems 7300 Real-Time PCR System) with 250 ng of ganglia
DNA or 50-100 ng vaginal swab DNA and primers specific to the
HSV DNA polymerase (Forward: 59 GCT CGA GTG CGA AAA
AAC GTT C, Reverse: 59 CGG GGC GCT CGG CTA AC) as
previously described [12]. The minimal copies of HSV-2 viral
DNA that could reliably be detected were one copy per reaction.
2.9. Statistical analysis
Un-paired Student’s t-tests were performed in the statistical
analysis of experimental results between sham-immunized animals
and gD2-alum/MPL immunized animals, sham-immunized ani-
mals and CJ2-gD2-immunized animals, and gD2-alum/MPL-
immunized animals and CJ2-gD2-immunized animals.
Results
3.1. CJ2-gD2 is highly effective against primary and
recurrent HSV-2 genital infections in guinea pigs
As an initial study in evaluating the vaccine efficacy of CJ2-gD2
in protecting against HSV-2 genital infection and disease, female
guinea pigs were first sham-immunized or immunized with CJ2-
gD2 at a dose of 5610
6 PFU/animal three times at two-week
intervals. At three weeks after the third immunization, the guinea
pigs were preswabbed and challenged intravaginally with
5610
5 PFU of HSV-2 strain MS. The results in Fig. 1 show that
immunization with CJ2-gD2 elicited a strong HSV-2-specific
neutralizing antibody response after boost immunization (Fig. 1A).
Importantly, the neutralizing antibody titers detected in CJ2-gD2-
immunized animals were significantly higher than those of the two
surviving sham-immunized animals at day 60 post-intravaginal
challenge with wild-type HSV-2 (p,0.01). Immunization with
CJ2-gD2 markedly reduced the acute intravaginal virus replication
of the challenge virus in the immunized animals compared with
the sham-immunized controls with a greater than 2,600-fold
(p=0.03) and 3,100-fold (p=0.02) reduction in challenge virus
yields on days 1 and 2 post-challenge, respectively (Fig. 1B). While
all the sham-immunized controls continued to shed virus with an
average yield of ,15,800 PFU/ml on day 7 and ,5,660 PFU/ml
on day 9 post-challenge, no virus shedding was detected in 5 of 6
CJ2-gD2-immunized animals by day 3 post-challenge. The
average duration of viral shedding in the CJ2-gD2-immunized
guinea pigs was 2.5 days compared with greater than 9 days in the
sham-immunized controls (p,0.001).
Consistent with these observations, CJ2-gD2 immunization is
very effective in protecting against primary (Fig. 1C and 1D) as
well as recurrent (Table 1) HSV-2 genital disease. While all the
sham-immunized animals developed multiple genital herpes
lesions following challenge with wild-type HSV-2 and four of six
animals died by day 17 post-challenge, only 1 of 6 CJ2-gD2-
immunized animals experienced a minor lesion on day 5, and that
animal was recovered by the next day. Similarly, immunization
with CJ2-gD2 led to a nearly 58-fold reduction in the incidence of
recurrent disease by the challenge wild-type virus in the
immunized animals compared with the sham-immunized controls
between days 18 and 60 post-challenge (p=0.001).
Prevention of HSV-2 Genital Disease in Guinea Pigs
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MPL subunit vaccine in eliciting HSV-2-specific
neutralizing antibody response
Fig. 2A represents the combined results from two independent
experiments, in which two sets of female Hartley guinea pigs were
sham-immunized with DMEM (n=8, 8), immunized with freshly
prepared gD2-alum/MPL (n=8, 6), or immunized with CJ2-gD2
(n=8, 6). The neutralizing antibody titers detected in the CJ2-
gD2-immunized animals are 5.5- and ,8-fold higher than those
detected in the gD2-alum/MPL-immunized animals after the
second and third immunizations, respectively (p,0.0001). Again,
Figure 1. CJ2-gD2 is highly effective in eliciting HSV-2-specific neutralizing antibodies and protective immunity against HSV-2
primary infection and disease in guinea pigs. Female Hartley guinea pigs were randomly assigned to two groups of six animals each and were
either sham-immunized with DMEM or immunized with CJ2-gD2 at a dose of 5610
6 PFU by intramuscular injection into the quadriceps of the left
and right hind limbs on days 0, 15, and 29. A. Blood was taken on days 14, 28, and 49 after the primary immunization or 60 days after challenge and
HSV-2-specific neutralizing antibodies in individual serums were determined. The results represent average titers 6 SEM. B. Three weeks after the
third immunization, guinea pigs were preswabbed and infected intravaginally with 5610
5 PFU of wild-type HSV-2 strain MS. Vaginal swabs were
taken on days 1, 2, 3, 5, 7, and 9 post-infection. Virus yields in swab materials were determined by standard plaque assay on Vero cell monolayers and
expressed as the mean 6 SEM for individual vaginal swabs. C and D. Following infection with wild-type HSV-2, sham-immunized and CJ2-gD2-
immunized guinea pigs were monitored daily from days 0 to 60 for the incidence of genital and disseminated HSV-2 disease. Presented is the disease
score for the first 20 days after challenge (C) and the percent of animals that experienced primary herpetic disease (D).
doi:10.1371/journal.pone.0101373.g001
Table 1. Immunization with CJ2-gD2 is highly effective in protecting against recurrent HSV-2 genital disease and the
establishment of latent infection.
Recurrent disease (days 18–60) Latent viral genome
Group
Percent Cumulative lesion/animal Frequency
a Percent Copy
b
Sham (n=2) 100% 19 9.5 100% 530, 27908
CJ2-gD2 (n=6) 33% 0.33 0.33 0% undetected
aRecurrent lesion days per animal between days 18 to 60 post challenge.
bLatent viral genome number per 250 ng DRG DNA in 2 surviving sham-immunized guinea pigs and CJ2-gD2-immunized animals on day 60 post challenge.
doi:10.1371/journal.pone.0101373.t001
Prevention of HSV-2 Genital Disease in Guinea Pigs
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e101373there was a significant increase in the HSV-2 neutralizing
antibody titers from the first to the second vaccination with an
average titer of ,1,990 after the second immunization and
,5,260 after the third immunization. The average HSV-2
neutralizing antibody titer in gD2-alum/MPL-immunized animals
was 364 after the second immunization and ,670 after the third
immunization. No HSV-2-specific neutralizing antibody was
detected in serum from the sham-immunized animals at 1:10-
dilution.
The western blot analysis with pooled serum prepared from
equal volume of gD2-alum/MPL immune animals (Fig. 2C) and
CJ2-gD2 immune animals (Fig. 2B) described in the first
experiment in section 2.3 demonstrates that in addition to the
gD2-specific antibody response, immunization with CJ2-gD2
elicits strong antibody responses to various HSV-2 antigens.
Expectedly, immunization with gD2-alum/MPL induced gD
antibody response only. These results also reveal that although
CJ2-gD2 is much less efficient in eliciting gD2-specific antibodies
than gD2-alum/MPL, the overall HSV-2-antibody response
elicited in CJ2-gD2-immunized animals was significantly higher
than the monovalent gD2 antibody response induced in gD2-
alum/MPL-immunized animals. Collectively, the results indicate
that the high-level neutralizing antibody titer detected in CJ2-gD2-
immunized animals can be attributed to its ability to elicit anti-
gD2 antibody response as well as antibody responses to various
other HSV-2 virion-associated envelop proteins. This finding is
consistent with the observations of Hoshino et al. [26] and Halford
et al. [27] reflecting that while immunization with gD2-alum/
MPL induces potent gD-specific antibody response, gD2-alum/
MPL is less superior in eliciting anti-HSV-2 neutralizing antibody
response compared with HSV-2 recombinant virus-based vaccine
candidates capable of eliciting antibody response to multiple HSV-
2 surface antigens.
3.3. CJ2-gD2 is more effective than gD2-alum/MPL in
protecting against acute replication of challenge HSV-2
as well as primary and recurrent HSV-2 genital disease
The sham-immunized and immunized animals described in
Fig. 2A were challenged intravaginally with wild-type HSV-2 as
detailed in the Materials and Methods. The results in Fig. 3A
showed that the yields of challenge virus in sham-immunized
controls were ,4610
6 PFU/ml, ,3.8610
6 PFU/ml, and
,3.1610
5 PFU/ml on days 1, 2, and 3 post-challenge, respec-
tively. The yields of challenge virus in the CJ2-gD2-immunized
animals were 1,600- (p,0.0001), and 3,000-fold (p=0.02) lower
than the sham-immunized animals on days 1 and 2 post-challenge,
respectively, and 71-fold lower than in the gD2-alum/MPL-
immunized animals on day 1 post-challenge (p=0.047). By day 5,
12 of 14 CJ2-gD2-immunized animals showed no virus shedding,
while 50% of the gD2-alum/MPL-immunized animals continued
to shed virus at an overall average yield of ,650 PFU/ml. The
duration of challenge virus shedding was 2.6 days in the CJ2-gD2-
immunized animals compared with 4.7 days in the gD2-alum/
MPL group (p=0.02) and 8.9 days in the sham-immunized
control (p,0.0001) (Fig. 3B).
The impact of immunization with CJ2-gD2 and gD2-alum/
MPL in protecting against primary skin lesions is summarized in
Fig. 4. All the sham-immunized animals developed multiple
genital herpetic lesions following challenge with wild-type HSV-2
and succumbed to HSV-2 infection by day 30 post-challenge. A
total of 515 lesions were detected in the sham-immunized animals
between days 5 and 7 post-challenge, while only one of fourteen
CJ2-gD2 immune animals exhibited 1 mild herpetiform lesion on
day 5 between days 1 and 11 post-challenge. Of the fourteen
animals immunized with gD2-alum/MPL, seven experienced
primary herpetic skin lesions with a total of 54 lesions detected
between days 4 and 8. Moreover, one of the gD2-alum/MPL
immunized animals had to be sacrificed on day 35 post-challenge
due to the severity of local and systemic herpetic disease, whereas
no CJ2-gD2-immunized animals showed any signs of neurological
illness. Collectively, the results demonstrate that CJ2-gD2 is
markedly superior to gD2-alum/MPL in protecting against HSV-
2 primary genital disease (Fig. 4B, p=0.013).
The results in Fig. 5 showed that immunization with CJ2-gD2 is
significantly more effective than immunization with gD2-alum/
MPL in protecting against recurrent HSV-2 genital disease in
terms of cumulative recurrent lesions per animal (0.29 vs. 2.9, p,
0.0001) and days on which animals exhibited recurrent disease
(0.29 vs. 2.7, p=0.046). In these studies, 79% of the CJ2-gD2-
immunized animals experienced no detectable recurrent disease
compared with 36% observed in the gD2-alum/MPL subunit
vaccine group (p=0.02).
Real-time PCR analysis of genital swab materials collected from
days 21 to 50, however, revealed that immunization with CJ2-gD2
did not offer significantly better protection against recurrent virus
shedding compared with immunization with the gD2 subunit
vaccine. Specifically, ten of fourteen guinea pigs in the CJ2-gD2
Figure 2. CJ2-gD2 is significantly more effective than gD2-
alum/MPL subunit vaccine in eliciting an HSV-2-specific
neutralizing antibody response in immunized guinea pigs. A.
Female Hartley guinea pigs were randomly assigned to three groups of
eight animals each in the first experiment and three groups of six to
eight each in the second experiment. They were either sham-
immunized with DMEM (n=8, 8), immunized with 3 mg of purified
recombinant gD2 freshly formulated with 7.5 mg of MPL and 75 mgo f
alum (n=8, 6) or immunized with CJ2-gD2 (n=8, 6) at a dose of
5610
6 PFU on days 0, 14, and 28. Blood was taken after the first,
second, and third immunizations as detailed in the Materials and
Methods. Heat inactivated serum from each animal was assayed
individually for HSV-2-specific neutralizing antibody titers on Vero cell
monolayers. The results represent average titers 6 SEM. B and C.
Western blot analysis with serum prepared from CJ2-gD2 (B)- and gD2-
alum/MPL (C)-immunized guinea pigs as detailed in the Materials and
Methods. Lanes 1, 2, and 3 represent cell extracts prepared from mock-
infected Vero cells, HSV-2-infected Vero cells, and gD2-transfected
U2OS cells, respectively.
doi:10.1371/journal.pone.0101373.g002
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immunized animals showed no detectable recurrent virus shed-
ding. The frequency of recurrent virus shedding from days 21 to
50 was 0.019 days/animal in the CJ2-gD2 group and 0.026 days/
animal in the gD2-alum/MPL-immunized group (p=0.67). The
average number of HSV-2 genome detected in vaginal swabs per
day from days 21 to 50 was 1.8 copies/animal in the CJ2-gD2
group and 3.2 copies/animal in the gD2-alum/MPL-immunized
group (p=0.25).
3.4. Immunization with CJ2-gD2 is highly effective in
protecting against the establishment of latent infection
by challenge HSV-2
At day 60 post-challenge, the dorsal root ganglia DNA were
harvested from all fourteen CJ2-gD2-immunized animals and the
thirteen surviving gD2-alum/MPL immunized animals. The
amount of viral DNA per guinea pig was determined by
quantitative real-time PCR. No challenge HSV-2 viral DNA
was detected in DRG DNA isolated from CJ2-gD2-immunized
guinea pigs, while four of fourteen gD2-alum/MPL-immunized
animals and all four sham-immunized animals euthanized on days
17, 18, 23, and 30 post-challenge, respectively, had detectable
latent HSV-2 viral DNA (Fig. 6).
Discussion
Various vaccine candidates have been investigated in the guinea
pig model of HSV-2 genital infection [19,28–30]. The subunit
vaccine gD2/AS04, which contains recombinant gD2 in combi-
nation with the adjuvant alum and MPL, was effective in
protecting against primary and recurrent HSV-2 genital disease
in immunized animals following intravaginal infection with wild-
type HSV-2 [20,31]. While in earlier phase III clinical trials at an
immunization dose of 20 mg of gD2 with 50 mg of MPL and
500 mg of alum, gD2/AS04 subunit vaccine provided 73–74%
efficacy in protecting against genital herpes disease in HSV-
seronegative women [23], no beneficial effect was observed in a
recent phase III clinical trial [24]. Since gD2/AS04 elicits little or
no CD8
+ T-cell response [1], and because CD8
+ T cells play a
crucial role in controlling HSV infection [32–39], these studies
have highlighted the importance of developing HSV vaccine
candidates enabling the induction of broader and more robust
humoral as well as CD4
+ and CD8
+ T-cell responses not only to
gD2 but also to other HSV antigens [1,7,28,40,41].
Unlike the replication-defective HSV-2 recombinant vaccine
constructs developed previously, i.e., dl5-29 [42], which can co-
replicate with wild-type virus or become replication competent in
the context of wild-type HSV-1 and HSV-2 infection, CJ2-gD2 is
a novel class of replication-defective HSV-2 recombinant viral
vaccine that encodes a potent trans-inhibitory activity capable of
blocking wild-type HSV-1 and HSV-2 viral replication in co-
infected cells. In addition to its unique capability of expressing
high levels of gD2 independent of HSV-2 viral DNA replication,
CJ2-gD2 expresses a wide array of HSV-2 antigens, such as the
viral immediate-early antigens ICP4, ICP27, ICP22; the early
antigens UL23, UL29, UL39, UL50; and the early-late antigens
UL18, UL19, UL49, UL55, and US8, which are the dominant
targets of CD8
+ T-cell response in HSV-2-infected individuals
[43–45]. We show that immunization with CJ2-gD2 elicits
Figure 3. CJ2-gD2 exhibits superior vaccine efficacy than gD2-
alum/MPL subunit vaccine in protecting against intravaginal
wild-type HSV-2 infection in guinea pigs. Female guinea pigs
sham-immunized with DMEM or immunized with gD2-alum/MPL or
CJ2-gD2 described in Fig. 2 were challenged intravaginally with
5610
5 PFU of HSV-2 strain MS. Vaginal swabs were taken on days 1,
2, 3, 5, 7, and 9 post-challenge. Infectious virus on swab materials was
determined by standard plaque assay in Vero cells. Viral yields are
expressed as the means 6 SEM for individual swabs (A). The duration of
viral shedding is represented as the mean number of days during which
infectious virus was detected in vaginal swabs 6 SEM (B).
doi:10.1371/journal.pone.0101373.g003
Figure 4. Prevention of primary HSV-2 genital disease in
guinea pigs immunized with CJ2-gD2. Sham-immunized, gD2-
alum/MPL- or CJ2-gD2-immunized guinea pigs described in Fig. 3 were
monitored daily during a 60-day follow-up period for the incidence of
genital and disseminated HSV-2 disease. The severity of disease was
scored: 0, no sign of disease; 1, redness or swelling; 2, a few small
vesicles; 3, several large vesicles; 4, several large ulcers with maceration;
5, paralysis; and 6, death. Presented are the disease scores for the first
21 days after challenge (A), the percent of animals that experienced
primary herpetic disease (B), and the percent of survival until day 60
after challenge (C).
doi:10.1371/journal.pone.0101373.g004
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+ and CD8
+ T-cell
responses in the immunized mice compared with the sham-
immunized control animals after infection with wild-type HSV-2.
Notably, the onset of the HSV-2-specific CD4
+ T cell response in
CJ2-gD2 immune mice is 2 days faster than the primary CD4
+ T-
cell response elicited in wild-type HSV-2 infected sham-immu-
nized control [13].
HSV employs various strategies to evade host immune
responses [46–53]. ICP0 and ICP47 are the two viral immedi-
ate-early proteins that involve in host immune evasion at a very
early stage of viral infection. ICP0 plays a key role in blocking
IFN-induced inhibition of viral infection [52,53] as well as the
TLR2/TLR9-mediated inflammatory cytokine response to HSV
infection [54]. Thus, in comparison with HSV recombinant viral
vaccines encoding functional ICP0, ICP0-null mutant-based
vaccine candidates, such as CJ2-gD2, are likely more active in
stimulating an innate host immune response, leading to enhanced
vaccine efficacy against HSV infection [55]. We showed that
immunization with CJ2-gD2 elicited strong antibody responses to
various HSV-2 antigens and yielded HSV-2-specific neutralizing
antibody titers 8-fold higher than those elicited by the gD2-alum/
MPL subunit vaccine after three immunizations.
Hoshino et al. revealed that, compared with immunization with
the gD2-alum/MPL, immunization with the replication-defective
HSV-2 viral vaccine, dl5-29, offered slightly better efficacy in
protecting against acute and recurrent HSV-2 genital disease in
HSV-1-seronegative guinea pigs and dl5-29 was also more
effective than the gD2-alum/MPL subunit vaccine in induction
of HSV-2 neutralizing antibody response [21]. Notably, the same
study showed that immunization with gD2-alum/MPL had little
effect in protecting against acute challenge virus replication in the
first 6 days post-challenge compared with sham immunization.
Consistent with findings of Bourne et al. [20,31] and Awashthi et
al. [19], in which animals were immunized with gD2-alum/MPL
twice or three times at a dose of 5 mg of gD2, we showed that
immunization with gD2-alum/MPL was very effective in protect-
ing against HSV-2 intravaginal infection. Compared with sham
immunization, immunization with the gD2-alum/MPL led to 23-
fold (p=0.0001), 508-fold (p=0.019), 442-fold (p=0.07), and 23-
fold (p=0.0001) reduction in challenge virus replication on days 1,
2, 3, and 5 post-challenge, respectively. Significantly, immuniza-
tion with CJ2-gD2 is more robust in blocking acute challenge virus
replication than the gD2-alum/MPL subunit vaccine. Yields of
challenge virus in CJ2-gD2-immunized animals were ,70-fold
lower than gD2-alum/MPL-immunized animals on day 1 post-
challenge, and 1600- and 3000-fold lower than sham-immunized
control on days 1 and 2 post-challenge, respectively. The duration
of challenge virus shedding was reduced to 2.6 days in CJ2-gD2-
immunized animals compared with 4.7 days in gD2-alum/MPL
group and 8.9 days in sham-immunized animals.
In accordance with its superiority in eliciting protective
immunity against acute HSV-2 replication, immunization with
CJ2-gD2 is also markedly superior to the gD2-alum/MPL in
protecting against primary as well as recurrent HSV-2 genital
disease. First, immunization with CJ2-gD2 provided nearly 100%
protection against primary genital lesions after challenge with
wild-type HSV-2. While 50% of gD2-alum/MPL-immunized
animals experienced primary herpetic skin lesions with a total of
54 lesions detected between days 4 and 8, only one of the fourteen
Figure 5. Prevention of recurrent HSV-2 disease in guinea pigs immunized with CJ2-gD2. After challenge with wild-type HSV-2, individual
guinea pigs described in the legend of Fig. 4 were monitored daily during a 60-day follow-up period for the incidence of genital and disseminated
HSV-2 disease. Presented are the cumulative numbers of recurrent lesions per animal (A), number of days that recurrent disease was experienced per
animal (B), and the percent of animals that experienced recurrent disease between days 21 to 60 after challenge (C).
doi:10.1371/journal.pone.0101373.g005
Figure 6. Protection from latent viral infection in guinea pigs
immunized with CJ2-gD2. Sixty days after challenge with wild-type
HSV-2, twelve lower lumbar and sacral dorsal root ganglia (DRG) per
guinea pig were collected from all fourteen CJ2-gD2-immunized guinea
pigs and the thirteen surviving gD2-alum/MPL-immunized guinea pigs.
As a control, the DRG DNA was also isolated from four sham-immunized
guinea pigs euthanized on days 17, 18, 23, and 30 post-challenge,
respectively, due to the severity of local and systemic illness caused by
HSV-2 infection. The total DNA was extracted and the presence of latent
viral DNA was quantified by quantitative real-time PCR. The HSV-2
genome number per guinea pig was determined and presented as
mean value. The guinea pig showing the highest viral DNA load in gD2-
alum/MPL group was the one euthanized on day 35 post-challenge.
doi:10.1371/journal.pone.0101373.g006
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lesion from days 1 to 11 post-challenge. Second, CJ2-gD2
immunization resulted in significantly lower rates of recurrent
disease in the immunized animals than did gD2-alum/MPL
immunization in terms of the incidence, cumulative recurrent
lesions per animal and days in which animals exhibited recurrent
disease. Third, while recurrent disease could be observed in gD2-
alum/MPL vaccinated animals as late as day 50 post-challenge, no
recurrent disease and recurrent virus shedding were detectable
after day 37 post-challenge in CJ2-gD2-immunized animals.
Lastly, no latent HSV-2 viral DNA was detectable in DRG of
CJ2-gD2-immunized animals harvested on day 60 after challenge
(Table 1 and Fig. 6); in contrast, four of fourteen gD2-alum/MPL
immunized animals had detectable latent HSV-2 viral DNA.
It has been documented that both dl5-29 and the gD2-alum/
MPL subunit vaccine are effective in reduction of recurrent HSV-
2 genital disease in HSV-1-seropositive guinea pigs [21].
Moreover, dl5-29 has been shown effective as a therapeutic
vaccine in reducing recurrent HSV-2 genital disease in guinea pigs
previously infected by HSV-2 [26]. Given that like dl5-29, CJ2-
gD2 is a replication-defective virus incapable of de novo viral
DNA replication, and its unique ability to express high levels of
gD2 independent of viral DNA replication, it is reasonable to
expect that CJ2-gD2 could also be an effective vaccine in
protecting against HSV-2 genital infection in HSV-1 seropositive
guinea pigs as well as a therapeutic vaccine against recurrent
HSV-2 genital infection and disease in guinea pigs.
To date, no vaccine capable of completely preventing HSV
infection has been reported. The induction of both effective
mucosal and systemic immune responses is likely required for
optimal protection against HSV genital infection. Given the recent
studies that intranasal immunization of gD/liposome complex
[56] or gD-IgG2a Fc fusion protein in CpG [57] can effectively
elicit HSV-2-specific mucosal immunity, it would be of great
interest to test whether the efficacy of CJ2-gD2 in eliciting mucosal
immune response can be enhanced by a prime/boost regimen
consisting of CJ2-gD2 and gD2 subunit vaccine [58,59].
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